206 related articles for article (PubMed ID: 1975166)
1. The clinical use of somatostatin analogues in the treatment of cancer.
Lamberts SW; Krenning EP; Klijn JG; Reubi JC
Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):29-49. PubMed ID: 1975166
[TBL] [Abstract][Full Text] [Related]
2. A guide to the clinical use of the somatostatin analogue SMS 201-995 (Sandostatin).
Lamberts SW
Acta Endocrinol Suppl (Copenh); 1987; 286():54-66. PubMed ID: 2892338
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
4. Future medical prospects for Sandostatin.
Harris AG
Z Gastroenterol; 1990 Sep; 28 Suppl 2():55-60. PubMed ID: 1980778
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging with 123I-Tyr3-Octreotide.
Lamberts SW; Reubi JC; Bakker WH; Krenning EP
Z Gastroenterol; 1990 Sep; 28 Suppl 2():20-1. PubMed ID: 1980773
[TBL] [Abstract][Full Text] [Related]
6. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
Lamberts SW; Bakker WH; Reubi JC; Krenning EP
Metabolism; 1990 Sep; 39(9 Suppl 2):152-5. PubMed ID: 2169572
[TBL] [Abstract][Full Text] [Related]
7. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin).
Lamberts SW
Acta Endocrinol Suppl (Copenh); 1986; 276():41-55. PubMed ID: 2875590
[TBL] [Abstract][Full Text] [Related]
8. Future medical prospects for Sandostatin.
Harris AG
Metabolism; 1990 Sep; 39(9 Suppl 2):180-5. PubMed ID: 2205787
[TBL] [Abstract][Full Text] [Related]
9. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptors: clinical implications for endocrinology and oncology.
Lamberts SW; de Herder WW; van Koetsveld PM; Koper JW; van der Lely AJ; Visser-Wisselaar HA; Hofland LJ
Ciba Found Symp; 1995; 190():222-36; discussion 236-9. PubMed ID: 7587649
[TBL] [Abstract][Full Text] [Related]
12. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
Wahid ST; Marbach P; Stolz B; Miller M; James RA; Ball SG
Eur J Endocrinol; 2002 Mar; 146(3):295-302. PubMed ID: 11888834
[TBL] [Abstract][Full Text] [Related]
13. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
14. Distribution of somatostatin receptors in normal and tumor tissue.
Reubi JC; Kvols L; Krenning E; Lamberts SW
Metabolism; 1990 Sep; 39(9 Suppl 2):78-81. PubMed ID: 2169575
[TBL] [Abstract][Full Text] [Related]
15. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.
Chanson P; Timsit J; Harris AG
Clin Pharmacokinet; 1993 Nov; 25(5):375-91. PubMed ID: 8287633
[TBL] [Abstract][Full Text] [Related]
18. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
19. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
Klijn JG; Hoff AM; Planting AS; Verweij J; Kok T; Lamberts SW; Portengen H; Foekens JA
Br J Cancer; 1990 Oct; 62(4):627-30. PubMed ID: 1977468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
